Source: Annual Congress 2009 - Emerging trends in the therapy of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. J. Barnes (London, United Kingdom). Reversing corticosteroid resistance. Annual Congress 2009 - Emerging trends in the therapy of COPD

Member's Comments

No comment yet.

Related content which might interest you: Reversing glucocorticoid resistance as a new therapeutic strategy Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Antibiotic management and resistance Source: Eur Respir Monogr 2018; 81: 312-330 Year: 2018 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Inhaled antibiotic therapy Source: Annual Congress 2013 –PG9 How to optimise antibiotic use in respiratory infections Year: 2013 Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002 Mechanisms of systemic side effects of inhaled steroids Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004 The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease Source: ERJ Open Res, 8 (1) 00491-2021; 10.1183/23120541.00491-2021 Year: 2022 Long-term macrolide therapy in chronic inflammatory airway diseases Source: Eur Respir J 2009; 33: 171-181 Year: 2009 Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001 Impact of therapies on insulin resistance in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010